In this article
Abbott delivered a robust performance in 2024, achieving a 10% increase in sales and a 13% rise in earnings per share (EPS) for the fourth quarter, excluding COVID-related revenues. CEO Robert Ford credited the company's commitment to innovation and operational excellence for its consistent growth across key segments. Notably, sales of continuous glucose monitors surged by 23%, while adult nutrition and diagnostics also posted significant gains.
Looking ahead to 2025, Abbott projects organic sales growth of 7.5% to 8.5% and an adjusted EPS range of $5.05 to $5.25. The company plans to continue investing in its portfolio, particularly in structural heart and cardiovascular devices, areas identified as key growth drivers during the earnings call.
While challenges like currency fluctuations and evolving tax regulations may arise, Abbott remains optimistic about sustaining its strong growth trajectory. With a focus on expanding innovation and maintaining market leadership, the company is well-positioned to build on its successes in the coming year.
